Ghassan Al-Jazayrly, MD
Hematology/Oncology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 41 years
- Graduated 1985
Offices
2 locations · Complete Care Community Health Center, Inc · 45 clinicians in this group
Hospitals listed: 757125 · Glendale Mem Hospital & Hlth Center · Hollywood Presbyterian Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Al-Jazayrly’s office at (323) 266-6700 to ask if they take your plan before you enroll.
California Medical Board record
Licence A52470 · Current
Licensed to practise in California · since 1993 · expires 2027-04-30 · University of Aleppo Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Glendale Mem Hospital & Hlth CenterGlendale, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.105, Oct 2024 – Sep 2025
- Hollywood Presbyterian Medical CenterLos Angeles, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.016, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.165, Oct 2024 – Sep 2025
See every measure and the patient survey for Glendale Mem Hospital & Hlth Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 6 the same, 1 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.105 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.94 (0 to 1.97) · 609 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.49 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 154.55 (98.55 to 210.56) · 42 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 75 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.9 · 325 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.6 · 373 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 166 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,586 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 3,962 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 4,083 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.07 (0.76 to 5.38) · 734 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.29) · 196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.98 (0.38 to 3.58) · 750 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.99 (0.29 to 17.7) · 201 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.34 (2.25 to 10.43) · 187 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.23) · 126 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.95) · 3,409 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.7 · 205 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.349 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.343 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.42 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.269 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 155 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -15.2 · 151 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.2 · 421 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.6 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.4 · 368 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.4 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 99 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 613 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 158 cases | No different | Jan 2024 – Dec 2024 |
What patients said (565 patients answered, 10% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 80% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Hollywood Presbyterian Medical Center
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 3 better, 4 the same, 0 worse of 7 measures. Readmissions: 1 better, 5 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.016 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.165 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0 to 1.95) · 687 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.51 to 1.21) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 140.36 (84.45 to 196.27) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 77 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.7 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.5 · 289 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,577 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 3,875 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,998 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.09 (1.83 to 6.36) · 761 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0 to 3.29) · 396 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.67 to 3.87) · 834 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.18 (0 to 14.44) · 416 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.49 (1.39 to 9.58) · 287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.18) · 172 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.36 (0 to 1.04) · 3,450 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 209 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.363 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.8 · 124 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 304 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -17.4 · 79 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.2 · 231 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 40.9 · 284 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 331 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.3 to 16.8) · 72 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,225 patients answered, 24% of those asked)
| Cleanliness | 2 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 66% |
| Doctors "always" communicated well | 69% |
| Staff "always" explained | 50% |
| Yes, staff "did" give patients this information | 79% |
| Yes, staff "did" give patients information about help after discharge | 75% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 67% |
| Doctors "always" treated them with courtesy and respect | 75% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 66% |
| Nurses "always" explained things so they could understand | 62% |
| Nurses "always" listened carefully | 63% |
| Nurses "always" treated them with courtesy and respect | 73% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 35% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Original Medicare doctor bills
$475,501
Medicare paid this office $475,501 for 228 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 159 | $95,200 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 175 | $27,743 | $129 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $20,350 | $112 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 16 | $3,011 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 11 | $2,992 | $55 |
See all 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 159 | $95,200 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 175 | $27,743 | $129 |
| Administration of chemotherapy into vein, 1 hour or less | 26 | $20,350 | $112 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 16 | $3,011 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 11 | $2,992 | $55 |
| Injection of drug or substance under skin or into muscle | 35 | $1,658 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $1 | None |
| Injection, denosumab, 1 mg | 23 | $1 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of bone marrow | 11 | – | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
228 Original Medicare patients in 2024. Average age 74 · Under 65 10% · 85 and older 18% · Women 50% · Also on Medicaid 93% · Health risk score 3.43. Sicker patients than 9 in 10 peers; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 69% · Chronic kidney disease 59% · Heart failure 54% · Coronary heart disease 51% · Depression 46% · Cancer 44% · COPD 44% · Atrial fibrillation 37% · Dementia 36% · Stroke 23%.
The office billed $927,581, Medicare allowed $597,948 and paid $475,501; for 5,459 services of 49 kinds; $318,827 of it was for drugs given in the office and $156,674 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 228 | 5,459 | 74 | 3.43 | $927,581 | $475,501 |
| 2023 | 197 | 10,940 | 75 | 3.20 | $406,452 | $162,365 |
| 2022 | 255 | 8,910 | 74 | 3.29 | $643,931 | $248,051 |
| 2021 | 267 | 9,904 | 74 | 3.56 | $766,802 | $298,794 |
| 2020 | 250 | 7,167 | 73 | 4.13 | $654,545 | $266,342 |
| 2019 | 315 | 9,650 | 73 | 3.74 | $616,189 | $233,526 |
| 2018 | 422 | 87,989 | 75 | 3.27 | $1,770,381 | $909,379 |
| 2017 | 535 | 159,809 | 73 | 3.20 | $2,839,510 | $1,227,741 |
| 2016 | 532 | 200,997 | 74 | 2.99 | $3,601,195 | $1,520,134 |
| 2015 | 591 | 208,026 | 74 | 3.22 | $3,336,963 | $1,436,642 |
| 2014 | 525 | 154,945 | 73 | 3.25 | $2,431,686 | $1,044,357 |
| 2013 | 608 | 63,740 | 73 | 3.02 | $2,439,085 | $1,117,875 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 143 | $106,724 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 157 | $26,637 | $142 |
| Administration of chemotherapy into vein, 1 hour or less | 20 | $16,929 | $114 |
| Injection of drug or substance under skin or into muscle | 27 | $1,319 | $10 |
| Injection, denosumab, 1 mg | 22 | $8 | None |
2022: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 196 | $145,360 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 202 | $43,365 | $162 |
| Administration of chemotherapy into vein, 1 hour or less | 27 | $24,832 | $115 |
| Injection, nivolumab, 1 mg | 15 | $7,960 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $3,436 | $26 |
| Administration of additional new drug or substance into vein, 1 hour or less | 13 | $2,426 | $58 |
| Injection of drug or substance under skin or into muscle | 33 | $2,183 | $11 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $2,097 | $25 |
| Injection, denosumab, 1 mg | 23 | $1 | None |
2021: 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 212 | $145,430 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 216 | $48,507 | $166 |
| Administration of chemotherapy into vein, 1 hour or less | 31 | $38,560 | $123 |
| Injection, bevacizumab, 10 mg | 14 | $22,817 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 21 | $8,399 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $7,171 | $63 |
| Administration of additional new drug or substance into vein, 1 hour or less | 19 | $6,576 | $62 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $3,023 | $25 |
| Injection of drug or substance under skin or into muscle | 34 | $2,140 | $10 |
| Administration of chemotherapy into vein, each additional hour | 13 | $1,631 | $26 |
| Injection, ondansetron hydrochloride, per 1 mg | 18 | $18 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $18 | None |
| Injection, denosumab, 1 mg | 25 | $1 | None |
2020: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 176 | $109,313 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 188 | $39,658 | $171 |
| Administration of chemotherapy into vein, 1 hour or less | 32 | $34,458 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 13 | $5,322 | $26 |
| Administration of additional new drug or substance into vein, 1 hour or less | 14 | $3,766 | $59 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $2,074 | $24 |
| Injection of drug or substance under skin or into muscle | 30 | $1,639 | $11 |
| Injection, denosumab, 1 mg | 28 | $1 | None |
2019: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 205 | $93,865 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 240 | $53,597 | $166 |
| Administration of chemotherapy into vein, 1 hour or less | 40 | $44,466 | $119 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 26 | $13,051 | $27 |
| Administration of additional new drug or substance into vein, 1 hour or less | 15 | $5,103 | $59 |
| Administration of chemotherapy into vein, each additional hour | 17 | $2,056 | $26 |
| Injection of drug or substance under skin or into muscle | 30 | $1,955 | $12 |
| Hospital discharge day management, 30 minutes or less | 11 | $750 | $63 |
| Biopsy of bone marrow | 11 | $730 | $66 |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $24 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 21 | $12 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 17 | $9 | None |
| Injection, denosumab, 1 mg | 23 | $1 | None |
| Injection, nivolumab, 1 mg | 11 | $1 | None |
2018: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 223 | $120,745 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 244 | $56,252 | $166 |
| Administration of chemotherapy into vein, 1 hour or less | 44 | $46,828 | $125 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 12 | $29,223 | None |
| Short return visit (20+ min) | 183 | $22,365 | $51 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $15,967 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 23 | $6,607 | $61 |
| Return visit (30+ min) | 41 | $6,494 | $93 |
| Administration of chemotherapy into vein, each additional hour | 19 | $3,608 | $28 |
| Injection of drug or substance under skin or into muscle | 17 | $3,258 | $17 |
| Biopsy of bone marrow | 17 | $1,868 | $110 |
| Hospital discharge day management, 30 minutes or less | 17 | $1,506 | $63 |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $212 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 27 | $118 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $50 | None |
2017: 21 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 270 | $96,249 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 44 | $74,426 | $123 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 280 | $58,465 | $163 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 15 | $47,581 | None |
| Short return visit (20+ min) | 238 | $46,818 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $23,590 | $28 |
| Return visit (30+ min) | 61 | $12,338 | $91 |
| Injection of drug or substance under skin or into muscle | 18 | $6,046 | $22 |
| Administration of chemotherapy into vein, each additional hour | 22 | $5,999 | $25 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $5,625 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $5,149 | $17 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 54 | $5,089 | $10 |
| Biopsy of bone marrow | 21 | $3,069 | $139 |
| New patient visit (45+ min) | 18 | $2,214 | $123 |
| New patient visit (30+ min) | 25 | $2,087 | $83 |
| Hospital discharge day management, 30 minutes or less | 20 | $2,053 | $62 |
| Insertion of needle into vein for collection of blood sample | 60 | $1,626 | $3 |
| Injection, ondansetron hydrochloride, per 1 mg | 33 | $451 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 21 | $239 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 27 | $201 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $117 | None |
2016: 23 services
| Injection, bevacizumab, 10 mg | 11 | $255,458 | None |
| Administration of chemotherapy into vein, 1 hour or less | 52 | $102,097 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 266 | $64,872 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 274 | $60,025 | $167 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 15 | $58,250 | None |
| Short return visit (20+ min) | 229 | $39,994 | $56 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 48 | $33,491 | $27 |
| Return visit (30+ min) | 53 | $10,195 | $89 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 77 | $9,342 | $10 |
| Injection, docetaxel, 1 mg | 11 | $8,839 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $8,629 | $56 |
| Administration of chemotherapy into vein, each additional hour | 30 | $6,956 | $25 |
| New patient visit (45+ min) | 47 | $6,278 | $134 |
| Injection of drug or substance under skin or into muscle | 26 | $4,684 | $23 |
| Insertion of needle into vein for collection of blood sample | 84 | $2,978 | $3 |
| Biopsy of bone marrow | 18 | $2,579 | $136 |
| Hospital discharge day management, 30 minutes or less | 14 | $1,360 | $62 |
| New patient visit (30+ min) | 11 | $1,028 | $93 |
| Injection, ondansetron hydrochloride, per 1 mg | 43 | $756 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $346 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 18 | $206 | $11 |
| Injection, diphenhydramine hcl, up to 50 mg | 25 | $137 | None |
| Infusion, normal saline solution, 250 cc | 13 | $31 | None |
2015: 24 services
| Administration of chemotherapy into vein, 1 hour or less | 48 | $86,684 | $121 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 21 | $76,294 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 351 | $71,546 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 306 | $65,957 | $61 |
| Short return visit (20+ min) | 207 | $35,469 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 49 | $30,835 | $26 |
| Injection, docetaxel, 1 mg | 15 | $23,346 | None |
| Return visit (30+ min) | 65 | $10,421 | $91 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $8,731 | $56 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 77 | $8,400 | $10 |
| Administration of chemotherapy into vein, each additional hour | 34 | $6,904 | $25 |
| Injection of drug or substance under skin or into muscle | 26 | $4,529 | $22 |
| New patient visit (45+ min) | 30 | $4,105 | $137 |
| Insertion of needle into vein for collection of blood sample | 82 | $2,652 | $3 |
| Biopsy of bone marrow | 17 | $2,417 | $142 |
| Hospital discharge day management, 30 minutes or less | 27 | $2,412 | $62 |
| New patient visit (30+ min) | 15 | $1,133 | $76 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $1,082 | $49 |
| Injection, ondansetron hydrochloride, per 1 mg | 47 | $604 | None |
| Infusion into a vein for hydration, each additional hour | 12 | $461 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 41 | $391 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 17 | $183 | $11 |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $110 | None |
| Infusion, normal saline solution, 250 cc | 39 | $102 | None |
2014: 23 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 277 | $68,819 | $60 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 298 | $67,879 | $167 |
| Administration of chemotherapy into vein, 1 hour or less | 45 | $62,365 | $119 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 17 | $55,771 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 51 | $26,346 | $26 |
| Short return visit (20+ min) | 208 | $21,371 | $50 |
| Return visit (30+ min) | 67 | $9,561 | $92 |
| Administration of additional new drug or substance into vein, 1 hour or less | 26 | $8,675 | $55 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $8,251 | $60 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 77 | $7,727 | $10 |
| Administration of chemotherapy into vein, each additional hour | 40 | $7,220 | $25 |
| New patient visit (45+ min) | 36 | $4,617 | $128 |
| Injection of drug or substance under skin or into muscle | 21 | $3,403 | $22 |
| Hospital discharge day management, 30 minutes or less | 28 | $2,810 | $61 |
| Insertion of needle into vein for collection of blood sample | 81 | $2,458 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $1,762 | $16 |
| Injection, paclitaxel, 30 mg | 12 | $1,523 | None |
| New patient visit (30+ min) | 16 | $1,407 | $88 |
| Injection, carboplatin, 50 mg | 14 | $1,253 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 42 | $557 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 34 | $295 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $139 | None |
| Infusion, normal saline solution, 250 cc | 21 | $28 | None |
2013: 22 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 326 | $79,477 | $58 |
| Administration of chemotherapy into vein, 1 hour or less | 39 | $70,332 | $129 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 338 | $68,832 | $163 |
| Short return visit (20+ min) | 238 | $35,101 | $56 |
| Injection, filgrastim (g-csf), 480 mcg | 15 | $33,273 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $24,880 | $28 |
| Administration of chemotherapy into vein, each additional hour | 30 | $12,082 | $27 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 151 | $9,436 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $8,136 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $7,075 | $67 |
| Insertion of needle into vein for collection of blood sample | 152 | $2,942 | $3 |
| New patient visit (30+ min) | 33 | $2,789 | $85 |
| Hospital discharge day management, 30 minutes or less | 29 | $2,726 | $59 |
| Biopsy of bone marrow | 18 | $2,522 | $140 |
| Injection of drug or substance under skin or into muscle | 17 | $2,230 | $23 |
| New patient visit (45+ min) | 17 | $2,197 | $129 |
| Return visit (30+ min) | 20 | $1,728 | $82 |
| Injection, ondansetron hydrochloride, per 1 mg | 34 | $634 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 31 | $223 | None |
| Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service | 18 | $188 | $10 |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $121 | None |
| Infusion, normal saline solution, 250 cc | 11 | $13 | None |
Medicaid work
$306,105 in 2024
Medicaid paid $306,105 for 6,456 billed services this clinician did in 2024, up to 149 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,285 | $261,635 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,996 | $32,447 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 322 | $10,763 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 318 | $554 |
| Return visit (30+ min) | 1,214 | $317 |
| Short return visit (20+ min) | 713 | $96 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 159 | $82 |
| 1ST HOSP IP/OBS HIGH 75 | 15 | $80 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 128 | $74 |
| New patient visit (30+ min) | 106 | $57 |
| Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure) | 19 | $0 |
| Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure) | 100 | $0 |
| 2024 | 6,456 | 13 | 149 | $306,105 |
| 2023 | 5,801 | 10 | 100 | $276,548 |
| 2022 | 7,612 | 17 | 233 | $421,652 |
| 2021 | 12,780 | 17 | 287 | $844,453 |
| 2020 | 12,006 | 17 | 267 | $877,618 |
| 2019 | 8,030 | 16 | 245 | $619,664 |
| 2018 | 5,623 | 12 | 259 | $335,954 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,030 | $201,991 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 2,241 | $59,496 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 275 | $12,778 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 317 | $1,394 |
| Return visit (30+ min) | 826 | $336 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 109 | $316 |
| New patient visit (30+ min) | 80 | $113 |
| Short return visit (20+ min) | 614 | $72 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 254 | $51 |
| Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 55 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 1,835 | $355,660 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,933 | $48,218 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 204 | $9,172 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 257 | $1,571 |
| Return visit (30+ min) | 1,308 | $1,211 |
| 1ST HOSP IP/OBS HIGH 75 | 13 | $1,026 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 56 | $799 |
| COMPREHENSIVE METABOLIC PANEL | 69 | $786 |
| CARCINOEMBRYONIC ANTIGEN | 32 | $688 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 72 | $626 |
| Short return visit (20+ min) | 1,154 | $570 |
| Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) | 38 | $551 |
2021
| Clinic visit/encounter, all-inclusive | 3,983 | $766,879 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,273 | $36,617 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 220 | $9,777 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 401 | $5,612 |
| Short return visit (20+ min) | 3,160 | $5,283 |
| CARCINOEMBRYONIC ANTIGEN | 177 | $3,763 |
| Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) | 256 | $3,488 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 212 | $3,367 |
| COMPREHENSIVE METABOLIC PANEL | 263 | $3,066 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 226 | $2,064 |
| Return visit (30+ min) | 957 | $1,521 |
| Short return visit | 912 | $1,332 |
2020
| Clinic visit/encounter, all-inclusive | 4,263 | $807,930 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,276 | $35,007 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 175 | $9,429 |
| Short return visit (20+ min) | 3,257 | $7,837 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 237 | $3,216 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 149 | $3,003 |
| Return visit (30+ min) | 676 | $2,441 |
| Short return visit | 1,096 | $2,097 |
| Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) | 131 | $2,065 |
| New patient visit (30+ min) | 312 | $1,515 |
| CARCINOEMBRYONIC ANTIGEN | 54 | $1,161 |
| COMPREHENSIVE METABOLIC PANEL | 102 | $1,085 |
2019
| Clinic visit/encounter, all-inclusive | 2,954 | $552,937 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,121 | $25,438 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 218 | $10,320 |
| Short return visit (20+ min) | 1,468 | $6,289 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 342 | $5,247 |
| Immunoassay for tumor antigen, quantitative; CA 15-3 (27.29) | 193 | $4,126 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 460 | $3,982 |
| Return visit (30+ min) | 529 | $3,715 |
| CARCINOEMBRYONIC ANTIGEN | 91 | $1,957 |
| COMPREHENSIVE METABOLIC PANEL | 106 | $1,258 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 135 | $1,191 |
| New patient visit (45+ min) | 119 | $1,044 |
2018
| Clinic visit/encounter, all-inclusive | 1,448 | $267,107 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 1,629 | $27,067 |
| Short return visit (20+ min) | 706 | $8,857 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 264 | $8,580 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure) | 276 | $7,051 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 341 | $5,076 |
| Return visit (30+ min) | 338 | $4,815 |
| New patient visit (30+ min) | 153 | $4,126 |
| OFF/OP EST MAY X REQ PHY/QHP | 71 | $1,170 |
| Injection, ondansetron hydrochloride, per 1 mg | 207 | $862 |
| Injection, dexamethasone sodium phosphate, 1 mg | 164 | $706 |
| 1ST HOSP IP/OBS HIGH 75 | 26 | $537 |
Drugs they prescribed that Part D paid
$3,892,633
Pharmacies billed $3,892,633 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (18 of 1,453) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
718 generic and 735 brand-name prescriptions · $3,892,633 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Opdivo | 88 | $630,988 | $7,170 |
| Keytruda | 43 | $457,744 | $10,645 |
| Yervoy | 29 | $441,664 | $15,230 |
| Xgeva | 113 | $318,179 | $2,816 |
| Avastin | 57 | $243,621 | $4,274 |
See all 34 drugs
| Opdivo | 88 | $630,988 | $7,170 |
| Keytruda | 43 | $457,744 | $10,645 |
| Yervoy | 29 | $441,664 | $15,230 |
| Xgeva | 113 | $318,179 | $2,816 |
| Avastin | 57 | $243,621 | $4,274 |
| Enhertu | 17 | $171,923 | $10,113 |
| Tecentriq | 17 | $163,643 | $9,626 |
| Procrit | 60 | $162,215 | $2,704 |
| Polivy | 14 | $143,758 | $10,268 |
| Rituxan | 23 | $131,840 | $5,732 |
| Lupron Depot | 63 | $120,122 | $1,907 |
| Prolia | 36 | $55,870 | $1,552 |
| Fulphila | 23 | $45,319 | $1,970 |
| Fulvestrant | 26 | $10,637 | $409 |
| Xarelto | 26 | $10,594 | $407 |
| Cyclophosphamide | 28 | $9,541 | $341 |
| Pemetrexed Disodium | 13 | $4,050 | $312 |
| Oxaliplatin | 29 | $2,827 | $97 |
| Megestrol Acetate | 13 | $1,219 | $94 |
| Gemcitabine | 16 | $1,010 | $63 |
| Ondansetron | 82 | $292 | $4 |
| Letrozole | 27 | $235 | $9 |
| Constulose | 11 | $213 | $19 |
| Hydrocodone-Acetaminophen | 12 | $206 | $17 |
| Gabapentin | 22 | $89 | $4 |
| Dexamethasone Sodium Phosphate | 53 | $81 | $2 |
| Pantoprazole | 19 | $77 | $4 |
| Diphenhydramine | 50 | $75 | $1 |
| Prednisone | 32 | $72 | $2 |
| Levothyroxine | 11 | $69 | $6 |
| Famotidine | 15 | $65 | $4 |
| Escitalopram | 15 | $59 | $4 |
| Ondansetron | 15 | $38 | $3 |
| Famotidine | 31 | $23 | $1 |
Year by year
| 2024 | 1,453 | 130 | 1% (18) | 51% | $3,892,633 |
| 2023 | 1,509 | 126 | 1% (13) | 46% | $4,708,537 |
| 2022 | 1,828 | 165 | 1% (15) | None | $4,991,274 |
| 2021 | 3,277 | 205 | 5% (160) | None | $5,806,124 |
| 2020 | 2,911 | 202 | 3% (84) | None | $5,786,035 |
| 2019 | 2,417 | 201 | 5% (129) | None | $4,894,797 |
| 2018 | 2,058 | 179 | 5% (100) | 23% | $3,120,567 |
| 2017 | 1,615 | 162 | 6% (99) | 20% | $1,887,616 |
| 2016 | 1,873 | 174 | 7% (127) | None | $1,807,707 |
| 2015 | 1,366 | 153 | 12% (163) | None | $1,152,683 |
| 2014 | 1,845 | 171 | 9% (159) | None | $1,350,485 |
| 2013 | 1,823 | 177 | 7% (134) | 21% | $1,021,747 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 42 drugs
| Opdivo | 71 | $641,573 | $9,036 |
| Keytruda | 47 | $556,595 | $11,842 |
| Yervoy | 23 | $346,304 | $15,057 |
| Xgeva | 104 | $294,059 | $2,827 |
| Lynparza | 13 | $216,193 | $16,630 |
| Tasigna | 11 | $199,932 | $18,176 |
| Rituxan | 24 | $176,319 | $7,347 |
| Lupron Depot | 63 | $129,691 | $2,059 |
| Avastin | 28 | $112,293 | $4,010 |
| Fulphila | 21 | $84,083 | $4,004 |
| Fulvestrant | 54 | $82,372 | $1,525 |
| Procrit | 21 | $71,359 | $3,398 |
| Prolia | 31 | $51,581 | $1,664 |
| Retacrit | 20 | $26,698 | $1,335 |
| Xarelto | 52 | $18,817 | $362 |
| Cyclophosphamide | 14 | $8,212 | $587 |
| Eliquis | 12 | $8,105 | $675 |
| Oxaliplatin | 26 | $6,572 | $253 |
| Gemcitabine | 22 | $2,053 | $93 |
| Megestrol Acetate | 11 | $1,590 | $145 |
| Letrozole | 60 | $1,581 | $26 |
| Divalproex | 12 | $351 | $29 |
| Famotidine | 31 | $256 | $8 |
| Pantoprazole | 21 | $254 | $12 |
| Ondansetron | 54 | $178 | $3 |
| Carbidopa-Levodopa | 13 | $138 | $11 |
| Alendronate | 11 | $134 | $12 |
| Ibuprofen | 28 | $128 | $5 |
| Dexamethasone Sodium Phosphate | 50 | $127 | $3 |
| Metoclopramide | 12 | $122 | $10 |
| Escitalopram | 20 | $113 | $6 |
| Valproic Acid | 16 | $112 | $7 |
| Levothyroxine | 12 | $101 | $8 |
| Diphenhydramine | 46 | $87 | $2 |
| Atorvastatin | 17 | $84 | $5 |
| Prednisone | 16 | $78 | $5 |
| Bisoprolol | 16 | $74 | $5 |
| Ondansetron | 16 | $71 | $4 |
| Albuterol Sulfate | 18 | $61 | $3 |
| Ipratropium | 17 | $54 | $3 |
| Furosemide | 11 | $41 | $4 |
| Famotidine | 26 | $36 | $1 |
2022: 48 drugs
| Opdivo | 88 | $708,301 | $8,049 |
| Yervoy | 29 | $472,603 | $16,297 |
| Afinitor | 25 | $413,502 | $16,540 |
| Xgeva | 125 | $335,543 | $2,684 |
| Ibrance | 21 | $329,567 | $15,694 |
| Verzenio | 19 | $241,552 | $12,713 |
| Venclexta | 13 | $120,773 | $9,290 |
| Avastin | 25 | $112,780 | $4,511 |
| Lupron Depot | 60 | $106,404 | $1,773 |
| Fulphila | 29 | $105,974 | $3,654 |
| Fulvestrant | 67 | $98,342 | $1,468 |
| Herceptin | 17 | $70,564 | $4,151 |
| Decitabine | 22 | $63,275 | $2,876 |
| Procrit | 17 | $61,413 | $3,613 |
| Prolia | 21 | $29,463 | $1,403 |
| Trelstar | 28 | $26,882 | $960 |
| Retacrit | 15 | $21,444 | $1,430 |
| Eliquis | 25 | $17,656 | $706 |
| Xarelto | 34 | $12,508 | $368 |
| Docetaxel | 14 | $8,445 | $603 |
| Exemestane | 13 | $3,340 | $257 |
| Oxaliplatin | 27 | $2,836 | $105 |
| Letrozole | 105 | $2,664 | $25 |
| Carboplatin | 26 | $1,562 | $60 |
| Loperamide | 17 | $1,512 | $89 |
| Paclitaxel | 14 | $1,346 | $96 |
| Fluorouracil | 15 | $1,188 | $79 |
| Gemcitabine | 12 | $744 | $62 |
| Duloxetine | 18 | $702 | $39 |
| Hydrocodone-Acetaminophen | 11 | $447 | $41 |
| Metoclopramide | 16 | $402 | $25 |
| Levothyroxine | 20 | $353 | $18 |
| Ibuprofen | 40 | $297 | $7 |
| Ondansetron | 74 | $294 | $4 |
| Gabapentin | 12 | $266 | $22 |
| Dexamethasone Sodium Phosphate | 23 | $255 | $11 |
| Ondansetron | 19 | $235 | $12 |
| Carbidopa-Levodopa | 17 | $193 | $11 |
| Anastrozole | 15 | $183 | $12 |
| Dexamethasone Sodium Phosphate | 56 | $178 | $3 |
| Pantoprazole | 17 | $149 | $9 |
| Diphenhydramine | 46 | $147 | $3 |
| Atorvastatin | 18 | $139 | $8 |
| Benztropine Mesylate | 11 | $114 | $10 |
| Famotidine | 14 | $114 | $8 |
| Alendronate | 15 | $94 | $6 |
| Sertraline | 15 | $91 | $6 |
| Famotidine | 23 | $47 | $2 |
2021: 78 drugs
| Opdivo | 62 | $697,631 | $11,252 |
| Ibrance | 42 | $604,401 | $14,391 |
| Avastin | 93 | $582,964 | $6,268 |
| Afinitor | 27 | $444,386 | $16,459 |
| Verzenio | 25 | $355,501 | $14,220 |
| Xgeva | 137 | $338,752 | $2,473 |
| Tukysa | 14 | $285,040 | $20,360 |
| Tasigna | 13 | $224,100 | $17,238 |
| Rituxan | 16 | $135,208 | $8,450 |
| Lupron Depot | 70 | $127,339 | $1,819 |
| Fulvestrant | 73 | $107,895 | $1,478 |
| Herceptin | 25 | $103,841 | $4,154 |
| Neulasta | 11 | $74,410 | $6,765 |
| Decitabine | 16 | $42,288 | $2,643 |
| Prolia | 24 | $31,920 | $1,330 |
| Eliquis | 44 | $31,818 | $723 |
| Trelstar | 31 | $26,696 | $861 |
| Retacrit | 27 | $25,554 | $946 |
| Doxorubicin Hcl Liposome | 14 | $22,371 | $1,598 |
| Xarelto | 30 | $16,703 | $557 |
| Oxycontin | 17 | $14,325 | $843 |
| Anagrelide | 38 | $12,384 | $326 |
| Docetaxel | 16 | $5,619 | $351 |
| Megestrol Acetate | 78 | $4,839 | $62 |
| Oxaliplatin | 49 | $4,588 | $94 |
| Symbicort | 11 | $4,366 | $397 |
| Hydrocodone-Acetaminophen | 103 | $3,787 | $37 |
| Letrozole | 214 | $3,507 | $16 |
| Ondansetron | 70 | $2,833 | $40 |
| Leucovorin | 13 | $2,603 | $200 |
| Fluorouracil | 36 | $2,159 | $60 |
| Loperamide | 27 | $2,053 | $76 |
| Lidocaine | 11 | $1,881 | $171 |
| Irinotecan | 18 | $1,577 | $88 |
| Bicalutamide | 47 | $1,569 | $33 |
| Gemcitabine | 18 | $1,536 | $85 |
| Cyclobenzaprine | 19 | $1,300 | $68 |
| Exemestane | 11 | $1,129 | $103 |
| Diclofenac | 32 | $988 | $31 |
| Carboplatin | 23 | $929 | $40 |
| Gabapentin | 53 | $868 | $16 |
| Rosuvastatin | 19 | $797 | $42 |
| Hydroxyurea | 14 | $796 | $57 |
| Ventolin Hfa | 13 | $765 | $59 |
| Baclofen | 25 | $738 | $30 |
| Omeprazole | 63 | $691 | $11 |
| Duloxetine | 30 | $606 | $20 |
| Levothyroxine | 37 | $481 | $13 |
| Anastrozole | 22 | $404 | $18 |
| Dexamethasone | 15 | $395 | $26 |
| Ondansetron | 102 | $385 | $4 |
| Prednisone | 60 | $368 | $6 |
| Oxybutynin Chloride | 17 | $334 | $20 |
| Pantoprazole | 36 | $323 | $9 |
| Zolpidem | 46 | $280 | $6 |
| Dexamethasone Sodium Phosphate | 100 | $254 | $3 |
| Atorvastatin | 33 | $242 | $7 |
| Tamsulosin | 13 | $218 | $17 |
| Potassium Chloride | 21 | $216 | $10 |
| Losartan | 15 | $216 | $14 |
| Alendronate | 40 | $213 | $5 |
| Alprazolam | 11 | $207 | $19 |
| Hydrocortisone | 27 | $199 | $7 |
| Metoclopramide | 21 | $192 | $9 |
| Losartan-Hydrochlorothiazide | 12 | $191 | $16 |
| Amlodipine Besylate | 31 | $181 | $6 |
| Sertraline | 37 | $154 | $4 |
| Ibuprofen | 14 | $142 | $10 |
| Diphenhydramine | 47 | $123 | $3 |
| Carbidopa-Levodopa | 11 | $120 | $11 |
| Benazepril | 19 | $115 | $6 |
| Famotidine | 19 | $112 | $6 |
| Azithromycin | 13 | $92 | $7 |
| Hydrochlorothiazide | 11 | $76 | $7 |
| Metoprolol | 14 | $69 | $5 |
| Triamcinolone Acetonide | 12 | $63 | $5 |
| Tramadol | 11 | $59 | $5 |
| Glipizide | 12 | $24 | $2 |
2020: 64 drugs
| Ibrance | 52 | $685,590 | $13,184 |
| Avastin | 60 | $476,001 | $7,933 |
| Opdivo | 65 | $445,838 | $6,859 |
| Yervoy | 25 | $390,116 | $15,605 |
| Xgeva | 156 | $340,226 | $2,181 |
| Xtandi | 20 | $245,335 | $12,267 |
| Lynparza | 16 | $237,823 | $14,864 |
| Enhertu | 29 | $228,549 | $7,881 |
| Afinitor | 14 | $207,707 | $14,836 |
| Rituxan | 19 | $153,141 | $8,060 |
| Zytiga | 14 | $142,175 | $10,155 |
| Keytruda | 14 | $135,870 | $9,705 |
| Tecentriq | 11 | $118,785 | $10,799 |
| Lupron Depot | 55 | $106,110 | $1,929 |
| Fulvestrant | 70 | $102,548 | $1,465 |
| Jakafi | 12 | $87,860 | $7,322 |
| Azacitidine | 21 | $76,939 | $3,664 |
| Empliciti | 13 | $69,445 | $5,342 |
| Aranesp | 27 | $51,179 | $1,896 |
| Anagrelide | 37 | $28,180 | $762 |
| Prolia | 22 | $26,339 | $1,197 |
| Eliquis | 40 | $26,172 | $654 |
| Xarelto | 47 | $22,766 | $484 |
| Toremifene Citrate | 12 | $13,470 | $1,123 |
| Cyclophosphamide | 22 | $9,079 | $413 |
| Symbicort | 15 | $8,654 | $577 |
| Megestrol Acetate | 78 | $4,524 | $58 |
| Letrozole | 225 | $2,559 | $11 |
| Lidocaine | 12 | $2,291 | $191 |
| Ondansetron | 62 | $1,993 | $32 |
| Hydrocodone-Acetaminophen | 57 | $1,321 | $23 |
| Baclofen | 20 | $1,036 | $52 |
| Diclofenac | 27 | $987 | $37 |
| Dexamethasone | 24 | $888 | $37 |
| Bicalutamide | 41 | $818 | $20 |
| Loperamide | 17 | $719 | $42 |
| Hydroxyurea | 15 | $713 | $48 |
| Duloxetine | 33 | $703 | $21 |
| Cyclobenzaprine | 15 | $673 | $45 |
| Albuterol Sulfate Hfa | 16 | $544 | $34 |
| Gabapentin | 55 | $478 | $9 |
| Potassium Chloride | 23 | $449 | $20 |
| Omeprazole | 70 | $432 | $6 |
| Ondansetron | 62 | $424 | $7 |
| Ibuprofen | 42 | $406 | $10 |
| Levothyroxine | 26 | $373 | $14 |
| Atorvastatin | 46 | $360 | $8 |
| Prednisone | 69 | $322 | $5 |
| Dexamethasone Sodium Phosphate | 63 | $260 | $4 |
| Pantoprazole | 41 | $243 | $6 |
| Zolpidem | 39 | $200 | $5 |
| Diphenhydramine | 54 | $183 | $3 |
| Anastrozole | 23 | $180 | $8 |
| Alendronate | 47 | $174 | $4 |
| Carbidopa-Levodopa | 13 | $141 | $11 |
| Hydrocortisone | 35 | $139 | $4 |
| Sertraline | 37 | $134 | $4 |
| Tamsulosin | 16 | $111 | $7 |
| Triamcinolone Acetonide | 14 | $85 | $6 |
| Famotidine | 18 | $68 | $4 |
| Allopurinol | 11 | $57 | $5 |
| Amlodipine Besylate | 15 | $56 | $4 |
| Tramadol | 12 | $39 | $3 |
| Benazepril | 12 | $38 | $3 |
2019: 58 drugs
| Afinitor | 49 | $759,268 | $15,495 |
| Ibrance | 39 | $472,634 | $12,119 |
| Opdivo | 37 | $418,797 | $11,319 |
| Tecentriq | 42 | $361,102 | $8,598 |
| Revlimid | 15 | $304,858 | $20,324 |
| Avastin | 43 | $260,923 | $6,068 |
| Xgeva | 74 | $171,962 | $2,324 |
| Rituxan | 12 | $128,489 | $10,707 |
| Keytruda | 14 | $106,094 | $7,578 |
| Velcade | 13 | $84,028 | $6,464 |
| Faslodex | 33 | $66,013 | $2,000 |
| Lupron Depot | 21 | $50,505 | $2,405 |
| Azacitidine | 12 | $35,758 | $2,980 |
| Zarxio | 11 | $29,430 | $2,675 |
| Xarelto | 45 | $23,345 | $519 |
| Prolia | 18 | $19,843 | $1,102 |
| Anagrelide | 43 | $16,686 | $388 |
| Eliquis | 39 | $16,382 | $420 |
| Oxycontin | 12 | $13,066 | $1,089 |
| Cyclophosphamide | 13 | $10,424 | $802 |
| Exemestane | 34 | $7,636 | $225 |
| Megestrol Acetate | 69 | $4,516 | $65 |
| Dexilant | 12 | $4,010 | $334 |
| Letrozole | 196 | $2,835 | $14 |
| Docetaxel | 15 | $2,179 | $145 |
| Gemcitabine | 12 | $2,075 | $173 |
| Hydrocodone-Acetaminophen | 72 | $1,578 | $22 |
| Carboplatin | 12 | $870 | $72 |
| Hydroxyurea | 24 | $790 | $33 |
| Gabapentin | 57 | $708 | $12 |
| Doxorubicin | 12 | $585 | $49 |
| Duloxetine | 27 | $547 | $20 |
| Ondansetron | 80 | $546 | $7 |
| Ondansetron | 55 | $481 | $9 |
| Levothyroxine | 31 | $445 | $14 |
| Dexamethasone | 18 | $411 | $23 |
| Bicalutamide | 16 | $367 | $23 |
| Tamoxifen Citrate | 11 | $346 | $31 |
| Anastrozole | 29 | $343 | $12 |
| Atorvastatin | 34 | $320 | $9 |
| Ranitidine | 15 | $307 | $20 |
| Omeprazole | 23 | $285 | $12 |
| Dexamethasone Sodium Phosphate | 64 | $242 | $4 |
| Pantoprazole | 33 | $230 | $7 |
| Ibuprofen | 25 | $204 | $8 |
| Hydromorphone | 19 | $204 | $11 |
| Diphenhydramine | 55 | $196 | $4 |
| Prednisone | 30 | $181 | $6 |
| Alendronate | 42 | $180 | $4 |
| Metoprolol | 11 | $171 | $16 |
| Zolpidem | 23 | $160 | $7 |
| Carbidopa-Levodopa | 12 | $127 | $11 |
| Metoclopramide | 12 | $102 | $9 |
| Hydrocortisone | 16 | $79 | $5 |
| Levofloxacin | 11 | $76 | $7 |
| Tramadol | 20 | $75 | $4 |
| Montelukast | 11 | $69 | $6 |
| Dexamethasone Sodium Phosphate | 12 | $64 | $5 |
2018: 53 drugs
| Afinitor | 30 | $445,352 | $14,845 |
| Ibrance | 26 | $301,251 | $11,587 |
| Stivarga | 18 | $292,679 | $16,260 |
| Jakafi | 16 | $206,465 | $12,904 |
| Pomalyst | 11 | $193,666 | $17,606 |
| Tasigna | 14 | $182,036 | $13,003 |
| Sutent | 15 | $180,700 | $12,047 |
| Opdivo | 12 | $147,718 | $12,310 |
| Rituxan | 13 | $145,363 | $11,182 |
| Neupogen | 15 | $49,891 | $3,326 |
| Procrit | 12 | $45,088 | $3,757 |
| Xgeva | 19 | $43,509 | $2,290 |
| Azacitidine | 12 | $32,585 | $2,715 |
| Anagrelide | 46 | $20,851 | $453 |
| Aranesp | 12 | $17,409 | $1,451 |
| Oxycontin | 11 | $11,754 | $1,069 |
| Xarelto | 25 | $10,336 | $413 |
| Eliquis | 23 | $9,122 | $397 |
| Megestrol Acetate | 54 | $3,224 | $60 |
| Leucovorin | 13 | $2,048 | $158 |
| Letrozole | 197 | $1,968 | $10 |
| Hydroxyurea | 25 | $1,331 | $53 |
| Hydrocodone-Acetaminophen | 57 | $1,176 | $21 |
| Anastrozole | 135 | $1,111 | $8 |
| Duloxetine | 41 | $1,019 | $25 |
| Tamoxifen Citrate | 33 | $989 | $30 |
| Ondansetron | 54 | $702 | $13 |
| Gabapentin | 69 | $602 | $9 |
| Levothyroxine | 32 | $516 | $16 |
| Carboplatin | 12 | $484 | $40 |
| Fluorouracil | 12 | $480 | $40 |
| Dexamethasone | 16 | $377 | $24 |
| Tamsulosin | 20 | $280 | $14 |
| Prednisone | 45 | $262 | $6 |
| Alendronate | 63 | $245 | $4 |
| Ondansetron | 40 | $239 | $6 |
| Metoclopramide | 31 | $236 | $8 |
| Metoprolol | 12 | $228 | $19 |
| Ibuprofen | 24 | $168 | $7 |
| Hydromorphone | 17 | $164 | $10 |
| Atorvastatin | 15 | $161 | $11 |
| Prochlorperazine Maleate | 14 | $155 | $11 |
| Dexamethasone Sodium Phosphate | 38 | $143 | $4 |
| Warfarin | 15 | $131 | $9 |
| Diphenhydramine | 27 | $122 | $5 |
| Zolpidem | 18 | $112 | $6 |
| Omeprazole | 14 | $112 | $8 |
| Dexamethasone Sodium Phosphate | 12 | $98 | $8 |
| Allopurinol | 11 | $90 | $8 |
| Pantoprazole | 18 | $83 | $5 |
| Benazepril | 12 | $69 | $6 |
| Furosemide | 15 | $32 | $2 |
| Potassium Chloride | 11 | $27 | $2 |
2017: 38 drugs
| Jakafi | 18 | $216,798 | $12,044 |
| Stivarga | 12 | $180,684 | $15,057 |
| Tasigna | 15 | $173,886 | $11,592 |
| Vectibix | 13 | $172,778 | $13,291 |
| Afinitor | 12 | $157,684 | $13,140 |
| Procrit | 31 | $117,653 | $3,795 |
| Anagrelide | 34 | $11,260 | $331 |
| Exemestane | 20 | $7,581 | $379 |
| Megestrol Acetate | 49 | $3,173 | $65 |
| Esomeprazole Magnesium | 17 | $2,331 | $137 |
| Letrozole | 163 | $1,704 | $10 |
| Duloxetine | 62 | $1,562 | $25 |
| Hydrocodone-Acetaminophen | 70 | $1,107 | $16 |
| Anastrozole | 117 | $1,091 | $9 |
| Tamoxifen Citrate | 29 | $895 | $31 |
| Gabapentin | 66 | $503 | $8 |
| Tamsulosin | 22 | $434 | $20 |
| Metoprolol | 14 | $391 | $28 |
| Hydroxyurea | 14 | $390 | $28 |
| Alendronate | 59 | $356 | $6 |
| Warfarin | 44 | $342 | $8 |
| Doxepin | 11 | $319 | $29 |
| Ondansetron | 27 | $252 | $9 |
| Prednisone | 42 | $244 | $6 |
| Diphenoxylate-Atropine | 11 | $191 | $17 |
| Spironolactone | 11 | $147 | $13 |
| Zolpidem | 20 | $128 | $6 |
| Pantoprazole | 21 | $125 | $6 |
| Hydromorphone | 11 | $124 | $11 |
| Quetiapine | 11 | $117 | $11 |
| Sertraline | 23 | $105 | $5 |
| Prochlorperazine Maleate | 14 | $77 | $6 |
| Ibuprofen | 18 | $65 | $4 |
| Donepezil | 11 | $62 | $6 |
| Benazepril | 11 | $61 | $6 |
| Famotidine | 11 | $56 | $5 |
| Amlodipine Besylate | 15 | $45 | $3 |
| Furosemide | 21 | $44 | $2 |
2016: 52 drugs
| Revlimid | 37 | $506,640 | $13,693 |
| Afinitor | 19 | $235,602 | $12,400 |
| Tasigna | 18 | $190,707 | $10,595 |
| Jakafi | 17 | $179,778 | $10,575 |
| Stivarga | 12 | $165,528 | $13,794 |
| Promacta | 11 | $96,926 | $8,811 |
| Procrit | 20 | $71,855 | $3,593 |
| Anagrelide | 32 | $10,990 | $343 |
| Xarelto | 19 | $8,177 | $430 |
| Eliquis | 12 | $3,914 | $326 |
| Crestor | 12 | $3,479 | $290 |
| Exemestane | 27 | $3,362 | $125 |
| Lyrica | 16 | $2,738 | $171 |
| Letrozole | 168 | $2,580 | $15 |
| Megestrol Acetate | 36 | $2,252 | $63 |
| Hydrocodone-Acetaminophen | 76 | $2,060 | $27 |
| Temazepam | 15 | $1,875 | $125 |
| Tolterodine | 11 | $1,626 | $148 |
| Tamoxifen Citrate | 43 | $795 | $18 |
| Ibandronate | 17 | $715 | $42 |
| Gabapentin | 100 | $675 | $7 |
| Anastrozole | 91 | $654 | $7 |
| Duloxetine | 19 | $528 | $28 |
| Warfarin | 73 | $434 | $6 |
| Tamsulosin | 29 | $381 | $13 |
| Ondansetron | 37 | $334 | $9 |
| Fenofibrate | 11 | $320 | $29 |
| Prednisone | 39 | $312 | $8 |
| Bicalutamide | 17 | $307 | $18 |
| Metoprolol | 12 | $276 | $23 |
| Metoclopramide | 40 | $270 | $7 |
| Diphenoxylate-Atropine | 18 | $240 | $13 |
| Hydromorphone | 18 | $240 | $13 |
| Alendronate | 43 | $238 | $6 |
| Quetiapine | 16 | $233 | $15 |
| Glyburide | 11 | $202 | $18 |
| Pantoprazole | 32 | $200 | $6 |
| Zolpidem | 40 | $191 | $5 |
| Doxepin | 11 | $186 | $17 |
| Spironolactone | 14 | $164 | $12 |
| Ibuprofen | 28 | $149 | $5 |
| Sertraline | 40 | $142 | $4 |
| Clopidogrel | 15 | $88 | $6 |
| Prochlorperazine Maleate | 14 | $76 | $5 |
| Sulfamethoxazole-Trimethoprim | 19 | $67 | $4 |
| Glipizide | 16 | $65 | $4 |
| Amiodarone | 11 | $64 | $6 |
| Famotidine | 17 | $61 | $4 |
| Furosemide | 17 | $61 | $4 |
| Donepezil | 12 | $56 | $5 |
| Alprazolam | 22 | $55 | $2 |
| Amlodipine Besylate | 15 | $47 | $3 |
2015: 37 drugs
| Revlimid | 32 | $377,039 | $11,782 |
| Erbitux | 20 | $156,005 | $7,800 |
| Thalomid | 11 | $94,758 | $8,614 |
| Exemestane | 20 | $5,234 | $262 |
| Lyrica | 27 | $4,423 | $164 |
| Hydrocodone-Acetaminophen | 91 | $2,985 | $33 |
| Temazepam | 17 | $2,738 | $161 |
| Megestrol Acetate | 29 | $2,621 | $90 |
| Morphine Sulfate Er | 18 | $730 | $41 |
| Letrozole | 79 | $686 | $9 |
| Anastrozole | 82 | $646 | $8 |
| Gabapentin | 72 | $544 | $8 |
| Tamoxifen Citrate | 17 | $439 | $26 |
| Metoprolol | 13 | $436 | $34 |
| Diphenoxylate-Atropine | 25 | $375 | $15 |
| Tamsulosin | 15 | $366 | $24 |
| Hydromorphone | 22 | $365 | $17 |
| Fenofibrate | 12 | $348 | $29 |
| Zolpidem | 21 | $343 | $16 |
| Nystatin | 13 | $330 | $25 |
| Bicalutamide | 19 | $285 | $15 |
| Warfarin | 33 | $252 | $8 |
| Metoclopramide | 45 | $248 | $6 |
| Levothyroxine | 17 | $245 | $14 |
| Ondansetron | 17 | $237 | $14 |
| Alendronate | 24 | $166 | $7 |
| Sertraline | 34 | $165 | $5 |
| Amlodipine Besylate | 19 | $132 | $7 |
| Enalapril Maleate | 12 | $130 | $11 |
| Pantoprazole | 11 | $124 | $11 |
| Glipizide | 25 | $117 | $5 |
| Famotidine | 15 | $96 | $6 |
| Ibuprofen | 12 | $92 | $8 |
| Sulfamethoxazole-Trimethoprim | 19 | $68 | $4 |
| Prednisone | 13 | $63 | $5 |
| Clopidogrel | 11 | $52 | $5 |
| Alprazolam | 11 | $47 | $4 |
2014: 49 drugs
| Revlimid | 26 | $291,595 | $11,215 |
| Tasigna | 22 | $194,485 | $8,840 |
| Erbitux | 18 | $147,853 | $8,214 |
| Sutent | 12 | $85,621 | $7,135 |
| Anagrelide | 30 | $22,491 | $750 |
| Nexium | 26 | $6,267 | $241 |
| Exemestane | 16 | $4,376 | $273 |
| Letrozole | 131 | $4,039 | $31 |
| Prochlorperazine Maleate | 16 | $2,421 | $151 |
| Tolterodine Tartrate Er | 12 | $2,167 | $181 |
| Hydrocodone-Acetaminophen | 65 | $2,141 | $33 |
| Anastrozole | 67 | $1,792 | $27 |
| Compro | 12 | $1,679 | $140 |
| Ibandronate | 15 | $1,584 | $106 |
| Megestrol Acetate | 41 | $1,504 | $37 |
| Gabapentin | 104 | $1,343 | $13 |
| Fluconazole | 24 | $995 | $41 |
| Oxycodone | 12 | $993 | $83 |
| Morphine Sulfate Er | 16 | $726 | $45 |
| Tamoxifen Citrate | 34 | $655 | $19 |
| Tamsulosin | 18 | $536 | $30 |
| Alendronate | 63 | $532 | $8 |
| Metoprolol | 17 | $523 | $31 |
| Hydromorphone | 30 | $498 | $17 |
| Levothyroxine | 34 | $417 | $12 |
| Warfarin | 52 | $409 | $8 |
| Dexamethasone | 16 | $393 | $25 |
| Amlodipine Besylate | 52 | $376 | $7 |
| Synthroid | 11 | $314 | $29 |
| Levofloxacin | 16 | $305 | $19 |
| Diphenoxylate-Atropine | 19 | $302 | $16 |
| Metoclopramide | 49 | $281 | $6 |
| Quetiapine | 15 | $259 | $17 |
| Famotidine | 27 | $225 | $8 |
| Zolpidem | 35 | $222 | $6 |
| Ondansetron | 23 | $220 | $10 |
| Lactulose | 13 | $219 | $17 |
| Omeprazole | 13 | $218 | $17 |
| Montelukast | 11 | $195 | $18 |
| Prednisone | 20 | $182 | $9 |
| Sertraline | 34 | $168 | $5 |
| Ibuprofen | 18 | $165 | $9 |
| Pantoprazole | 19 | $129 | $7 |
| Atorvastatin | 13 | $127 | $10 |
| Allopurinol | 11 | $79 | $7 |
| Alprazolam | 14 | $72 | $5 |
| Donepezil | 11 | $66 | $6 |
| Metformin | 12 | $60 | $5 |
| Benazepril | 11 | $43 | $4 |
2013: 45 drugs
| Revlimid | 22 | $255,732 | $11,624 |
| Tasigna | 29 | $231,804 | $7,993 |
| Sutent | 11 | $62,483 | $5,680 |
| Thalomid | 11 | $46,850 | $4,259 |
| Docetaxel | 14 | $37,728 | $2,695 |
| Anagrelide | 48 | $16,723 | $348 |
| Nexium | 43 | $9,289 | $216 |
| Letrozole | 199 | $5,409 | $27 |
| Xarelto | 12 | $3,463 | $289 |
| Lyrica | 16 | $2,975 | $186 |
| Megestrol Acetate | 34 | $2,410 | $71 |
| Carboplatin | 13 | $1,914 | $147 |
| Ibandronate | 17 | $1,801 | $106 |
| Prochlorperazine Maleate | 14 | $1,318 | $94 |
| Anastrozole | 35 | $908 | $26 |
| Alendronate | 86 | $796 | $9 |
| Fluconazole | 27 | $761 | $28 |
| Hydrocodone-Acetaminophen | 57 | $660 | $12 |
| Gabapentin | 75 | $600 | $8 |
| Hydroxyurea | 27 | $595 | $22 |
| Ondansetron | 28 | $554 | $20 |
| Omeprazole | 30 | $475 | $16 |
| Hydromorphone | 24 | $462 | $19 |
| Dexamethasone | 19 | $443 | $23 |
| Diclofenac | 18 | $439 | $24 |
| Tamoxifen Citrate | 24 | $377 | $16 |
| Warfarin | 54 | $366 | $7 |
| Metoclopramide | 53 | $355 | $7 |
| Amlodipine Besylate | 56 | $353 | $6 |
| Montelukast | 13 | $300 | $23 |
| Famotidine | 33 | $293 | $9 |
| Glyburide | 12 | $209 | $17 |
| Levothyroxine | 21 | $205 | $10 |
| Tamsulosin | 12 | $185 | $15 |
| Ibuprofen | 32 | $182 | $6 |
| Naproxen | 20 | $150 | $8 |
| Levofloxacin | 16 | $150 | $9 |
| Zolpidem | 19 | $147 | $8 |
| Tramadol | 16 | $143 | $9 |
| Prednisone | 26 | $127 | $5 |
| Atenolol | 20 | $86 | $4 |
| Simvastatin | 12 | $74 | $6 |
| Sertraline | 11 | $62 | $6 |
| Alprazolam | 15 | $61 | $4 |
| Benazepril | 11 | $54 | $5 |
Money from drug and device companies
$117 in 2025
| 2025 | 4 | 5 | None | $117 |
| 2024 | 2 | 2 | None | $57 |
| 2023 | 3 | 3 | None | $161 |
| 2022 | 1 | 1 | None | $20 |
| 2021 | 1 | 1 | None | $65 |
| 2020 | 12 | 22 | None | $412 |
| 2019 | 18 | 76 | None | $1,253 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Opdualag | $48 | 2 payments
|
| Incyte | Jakafi | $26 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
| Gilead Sciences | Trodelvy | $20 | 1 payment
|
See all 5 published payments
| Gilead Sciences | Meals · 2025-09-17 | Trodelvy | $20 |
| Eisai | Meals · 2025-08-27 | Lenvima | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-20 | Opdualag | $21 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-14 | Opdualag | $26 |
| Incyte | Meals · 2025-01-14 | Jakafi | $26 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $57
| Adaptive Biotechnologies | Clonoseq | $35 | 1 payment
|
| Abbvie | Elahere | $21 | 1 payment
|
2023: $161
| Incyte | Monjuvi | $125 | 1 payment
|
| Novocure | Optune | $21 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | None | $16 | 1 payment
|
2022: $20
| Pfizer | Ibrance | $20 | 1 payment
|
2021: $65
| Lilly USA | Verzenio | $65 | 1 payment
|
2020: $412
| E.R. Squibb & Sons L.L.C. | Opdivo | $92 | 5 payments
|
| Merck Sharp & Dohme | Keytruda | $63 | 4 payments
|
| Novartis Pharmaceuticals | Kisqali | $49 | 2 payments
|
| Pfizer | Ibrance | $46 | 3 payments
|
| Puma Biotechnology | Nerlynx | $25 | 1 payment
|
| Daiichi Sankyo | Enhertu | $25 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $21 | 1 payment
|
| Genentech USA | Tecentriq | $20 | 1 payment
|
| GlaxoSmithKline | Zejula | $18 | 1 payment
|
| Mylan Institutional | Ogivri | $17 | 1 payment
|
| Advanced Accelerator Applications | Lutathera | $15 | 1 payment
|
2019: $1,253
| E.R. Squibb & Sons L.L.C. | Opdivo | $295 | 23 payments
|
| Genentech USA | Tecentriq | $178 | 7 payments
|
| Pfizer | Ibrance | $147 | 16 payments
|
| Merck Sharp & Dohme | Keytruda | $108 | 6 payments
|
| Amgen | Nplate | $92 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $74 | 4 payments
|
| Gilead Sciences | None | $63 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $60 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $33 | 1 payment
|
| Exelixis | Cabometyx | $30 | 1 payment
|
| Tesaro | Zejula | $29 | 1 payment
|
| Janssen Biotech | Darzalex | $24 | 1 payment
|
| Novartis Pharmaceuticals | Mekinist | $24 | 1 payment
|
| Lilly USA | Alimta | $23 | 1 payment
|
| Eisai | Lenvima | $22 | 1 payment
|
| Advanced Accelerator Applications | Lutathera | $18 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $18 | 1 payment
|
| Genzyme | Cablivi | $14 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Seagen Inc. · A Phase 1 Study of Sgn-Tgt in Subjects With Advanced Malignancies · 2023 | Their institution | $82,166 |
| Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2025 | Their institution | $53,820 |
| PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2024 | Their institution | $30,617 |
| Amgen Inc. · A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Amg 193 Alone and in Combination With Docetaxel in Subjects With Advanced Mtap-Null Solid Tumors · 2025 | Their institution | $29,000 |
| PFIZER INC. · A Phase 1 Study of Sgntgt in Subjects With Advanced Malignancies · 2024 | Their institution | $24,128 |
| Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2023 | Their institution | $20,000 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2022 | Their institution | $20,000 |
| Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2021 | Their institution | $15,817 |
| Merck Sharp & Dohme LLC · An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of Inbrx 106 and Inbrx-106 in Combination With Pembrolizumab in Subjects With Locally Advanced Or Metastatic Solid Tumors · 2024 | Their institution | $15,760 |
| Veru Inc. · Veru V3002401 4063 01 · 2023 | Their institution | $15,695 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2022 | Their institution | $13,715 |
| BioNTech SE · 2022 | Their institution | $13,500 |
| AstraZeneca UK Limited · An Observational,Prospective,Multicenter Study of Non Small Cell Lung Cancer Patients in the US Receiving Standard of Care and Initiating An Approved Therapy With Risk of Pneumonitis Ild · 2025 | Their institution | $12,755 |
| Daiichi Sankyo Inc. · Enhertu · 2025 | Their institution | $12,302 |
| Exeltis, USA Inc. · Slynd · 2024 | Their institution | $11,800 |
| AstraZeneca UK Limited · An Observational,Prospective,Multicenter Study of Non Small Cell Lung Cancer Patients in the US Receiving Standard of Care and Initiating An Approved Therapy With Risk of Pneumonitis Ild · 2024 | Their institution | $10,100 |
| Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2022 | Their institution | $9,714 |
| Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2022 | Their institution | $8,269 |
| Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2024 | Their institution | $7,850 |
| Eli Lilly and Company · A Phase 3 Open-Label Randomized Study of Pirtobrutinib (Loxo-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2023 | Their institution | $6,274 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Randomized Phase 3 Multicenter Open-Label Study To Compare the Efficacy of Tak-788 As First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations · 2023 | Their institution | $5,150 |
| Becton, Dickinson and Company · 2021 | Their institution | $5,000 |
| PFIZER INC. · A Phase 3 Randomized Openlabel Multicenter Trial of Arv471 Pf07850327 Vs Fulvestrant in Participants With Estrogen Receptorpositive Her2negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease Veritac2 · 2025 | Their institution | $4,495 |
| Incyte Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Pi3kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis · 2025 | Their institution | $4,000 |
| Incyte Corporation · A Randomized, Double-Blind, Placebo-Controlled Study of the Pi3kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response To Ruxolitinib · 2025 | Their institution | $4,000 |
| Amgen Inc. · A Phase 1 Fih Prmt5i Therapy for Treatment of Mtap Null Nscls · 2024 | Their institution | $2,680 |
| Amgen Inc. · P3 1l Crc Triplet Cb 301 · 2024 | Their institution | $1,504 |
| BioNTech SE · 2024 | Their institution | $1,414 |
| Daiichi Sankyo Inc. · 2025 | Their institution | $1,401 |
| Eli Lilly and Company · Study of Loxo-305 Versus Investigator'S Choice (Idelar Or Br) in Patients With Previously Treated Chronic Lymphocytic Leukemia (Cll)/Small Lymphocytic Lymphoma (Sll) (Bruin Cll-321) · 2023 | Their institution | $1,261 |
| Eli Lilly and Company · A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (Loxo-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 2024 | Their institution | $9 |
Professional record
- NPI
- 1679590566
- Licence
- CA A52470California A52470: Current · expires 2027-04-30
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A524700
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- Po Box 6, La Canada, CA, 91012
- NPI first listed
- 2006-07-16
- NPI last updated
- 2007-07-09
This is when the NPI record was last certified, not a medical board exam.